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ABSTRACT
Dual Targeting of the Mesenchymal and Amoeboid Pathways:
A Viable Therapy against Metastatic Breast Cancer
Brandon C. Jones

Metastasis from the primary tumor site is the major cause of death in breast cancer, and
acquisition of migration capacity is a key element for successful metastasis. Recently, it was
found that expression of NEDD9, a focal adhesion associated scaffolding protein, could be used
to switch between two types of single cell movement known as mesenchymal and amoeboid.
Control of this “switch” can potentially open up new avenues of treatment against cancer
metastasis. Simultaneous inhibition of both types of single cell movement may prevent cancer
migration, thus decreasing cancer spreading and increasing survival of cancer patients. For
example, forcibly pushing the switch toward amoeboid migration in combination with treatment
against the kinase ROCK, a key component of amoeboid movement, might prove to be a vital
strategy against metastasis. Currently, such strategies are not available in clinical practice. This
project seeks to fill this gap in knowledge and provide new migration-based strategies to treat
breast cancer metastases by 1) defining the impact of NEDD9 expression on regulation of
mesenchymal invasion in breast cancer cells, 2) deciphering the mechanism and characterizing
the key downstream effectors of NEDD9-dependent signaling that contribute to breast cancer
mesenchymal migration, and 3) determining the anti-metastatic therapeutic benefit of inhibiting
both mesenchymal and amoeboid breast cancer cell movement in vitro and in vivo.
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CHAPTER 1: LITERATURE REVIEW

I. Breast Cancer
1.1: Importance of Breast Cancer Research
Despite all advances in the field of breast cancer research, breast cancer remains the
most commonly diagnosed cancer for women in the United States, as well as the second highest
cause of cancer death in women behind lung cancer (1). It is estimated that 1 in 8 women
(12.3%) in the United States will be diagnosed with breast cancer in their lifetime (2). This risk
increases with age - the median age for women diagnosed with BC was 61 years old in 2015
(2). The American Cancer Society projects that in 2017 there will be over 250,000 newly
diagnosed cases and over 40,000 new deaths as a result of invasive breast cancer (cancer.org).
These startling statistics showcase a critical need for rapid advancements in therapeutic
strategies against the invasive potential of this disease.

1.2: Triple Negative Breast Cancer
The search for targetable biomarkers of breast cancer has yielded a few favorable targets
with encouraging therapies. Around 60-70% of breast cancers have been found to have high
expression of hormone receptors for estrogen or progesterone (3). Much success has been
had against such cancers using hormone-targeting therapies like tamoxifen, which binds and
inhibits estrogen receptor signaling, or aromatase inhibitors which suppress estrogen
production (4, 5). Another 15% of breast cancers are positive for amplification of the oncogene
HER2 (also referred to as HER2/neu or erbB2) (3). This gene codes for a receptor tyrosine
kinase that complexes with other members of its family (EGFR/erbB1, erbB3, and erbB4) on
the cell surface. Treatment against HER2-positive cancers has had much success using
monoclonal antibody trastuzumab therapy (6, 7).
1

Breast cancers that are negative for expression of ER, PR, and HER2 are referred to as
triple negative breast cancer (TNBC). TNBC comprises about 15-20% of all BC and is
associated with increased tumor cell proliferation, substantial invasion and metastasis, and
much poorer patient survival in comparison to other BCs (8, 9). TNBC is also associated with
a higher incidence in mutation of the breast cancer tumor suppressor genes BRCA1 and
BRCA2, which help maintain DNA integrity and control proper cell division/apoptosis (10, 11).
The diminished survival rate of TNBC is not only due to the rampant aggressiveness of
the disease, but also because of a decrease in the extent of applicable therapies. The lack of
ER/PR/HER2 diminishes the number of available proven targeted treatment options, with
cytotoxic chemotherapy being the main approved regimen (8). Circumstances of
chemoresistance restrict potential remedies even further, unfortunately leaving very limited
options. While breast cancer death rates have been on the decline in older women, they have
remained fairly steady for women younger than 50 (cancer.org). This may be linked to TNBC
being more commonly diagnosed in younger women (<50 years), who do not have as many
treatment options as other BCs (8, 10).

II. Metastasis and Types of Invasion
2.1: Metastasis
Metastasis of cancer cells from the primary tumor site is the most life-threatening aspect
in the majority of diagnosed cancer cases. This involves a phenomenon known as epithelial-tomesenchymal transition or EMT, where normal epithelial cells lose their polarity and cell-cell
adhesions to become invasive mesenchymal cells (12). These cells can then invade neighboring
tissues or break through the basement membrane into the blood stream by intravasation and be
carried to a distant site in the body for further colonization. Once cancerous cells are able to
enter the blood stream, survival rate of the patient is likely to decrease at an accelerated rate.
2

Cancer cells are capable of migrating either collectively or individually (13-16). Individual
invasive cells lose all cell-cell adhesions and are known to be able to invade via two different
methods of migration known as mesenchymal and amoeboid (17-19). Depending upon
conditions such as extracellular matrix (ECM) composition, pore size, and rigidity of the cell
microenvironment, these two methods can be used interchangeably by the same cell population
in order to invade into different areas (14, 18). For example, since the interstitial matrices of the
human body are heterogeneous - ranging from loose fibrillary regions to dense connective tissue
- macrophages have been shown to utilize both mesenchymal and amoeboid migration to
navigate such environments and reach different tissue sites (20-22). The switching between
these two modes is referred to as mesenchymal-to-amoeboid transition (MAT) and amoeboidto-mesenchymal transition (AMT).

2.2: Overview of Mesenchymal Invasion
Mesenchymal migration is characterized by an elongated cell phenotype and the
construction of lamellipodia actin structures at the mobile leading edge of the cell (17).
Fibroblasts are commonly associated with this type of cell movement (23). The lamellipodium at
the leading edge beneath the membrane is a typically broad treadmilling branched-actin
meshwork, and helps to propel the cell across the microenvironment (24). Cell-matrix adhesion
interactions, consisting of integrins and signaling protein clusters at the membrane that act as
hubs between the extracellular matrix outside and the actin cytoskeleton inside, are quite strong
in mesenchymal movement (17). This allows the leading edge of the cell to reach out, get a firm
“grip” with the focal adhesions, and then follow up by pulling in the cell rear (23). In addition to
this, mesenchymal movement is also characterized by the formation of invadopodia (25). These
long actin basal ventral membrane protrusions extend from the cell membrane for the purpose
of matrix degradation. Through the activation of enzymes called matrix metalloproteinases or
3

MMPs at invadopodia membrane sites, the cell can cut holes through the ECM in order to clear
a viable path for cell movement (17, 23). This ability to degrade matrix makes mesenchymal
movement less restricted by the pore size of any given substratum, even allowing it to dig into
bones (26).
MMPs are especially useful for invasion of the basement membrane (BM), which is a
dense matrix that lines the epithelium and endothelium layers and can act as a physical barrier
to metastatic cells invading and entering the circulatory system. A dense reconstituted protein
mixture that is prepared from mouse sarcoma is often used to experimentally test the ability of
mesenchymal cells to invade basement membrane. This protein mixture, most commonly
marketed under the name Matrigel, contains many ECM proteins including laminin, collagen IV,
entactin, fibronectin, and vitronectin, thus making it a good representation of BM (27). The
density and rigidity of this matrix makes mesenchymal movement ideal for invasion in such
applications.

2.3: Overview of Amoeboid Invasion
Amoeboid migration is characterized by a more rounded cell phenotype and the
contractility of cortical actomyosin fibers (17, 28). These tense contractile forces aid in the
movement of the cell across matrices and can also result in representative blebbing of the cell
membrane. This method of movement does not usually utilize matrix metalloproteinases, and
instead deforms cell shape to squeeze through preexisting gaps or uses its contractile forces to
slightly widen holes in the ECM (29). Due to its lack of use of MMPs, amoeboid movement is
restricted in tissue with rigid highly crosslinked matrices like BM or bone, instead being most
suited for invasion through less dense and more flexible microenvironments such as collagen I
(20). Collagen I is the most abundant protein in human connective tissue and breast
microenvironment,

making

it

an

excellent
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physiological

representation

of

tumor

microenvironment when used in experimental studies (30). Common cells to use this type of
movement are leukocytes such as neutrophils or monocytes, which do not require MMP
enzymes to freely navigate through the flowing blood stream (23).
Another point of difference is that cell-matrix adhesion interactions are diffuse and thus
overall weaker in amoeboid cells in comparison to mesenchymal cells (17). This may provide
an explanation for why amoeboid movement has been shown to be faster than mesenchymal in
some reports, as the cells could quickly rearrange focal adhesions while rolling through existing
holes in the ECM. The speed at which amoeboid cells can move is heavily linked to their
microenvironment and the pore size of the extracellular matrix. The smaller the pore, the more
difficult it is for the cell to deform its shape and squeeze through. The greatest limiting factor for
the cell is the deformation of its nucleus, which must deform enough to squeeze through tight
spaces but also be resilient enough to not rupture (28, 31). Complete arrest of amoeboid cell
migration has been shown to occur when the pore size reaches about 10% of the nuclear cross
section – for tumor cells, this is typically about 7µm2 (28). Nuclear lamin concentrations have
been shown to play a large role in nuclear deformability regulation during amoeboid movement
(31). Lamin proteins make up the main structural component of the nucleus, where they line the
inside of the nuclear membrane to provide mechanical stability and scaffolding functions for
protein and chromatin binding (32). Loss of lamin has no effect on migration ability through large
pores, but severely hinders invasion through small pores due to compromise of the nuclear
envelope. Likewise, too high of a lamin concentration makes it more difficult for the nucleus to
deform, which can also hinder amoeboid invasion.

2.4: Collective Invasion
In collective migration, cells actually retain much of their epithelial characteristics such as
cell-cell adhesions and invade in bonded layers. The cells at the leading edge of the sheet
5

typically have mesenchymal and proteolytic characteristics that allow for degradation of the
matrix and pulling along of the sheet. Common physiological uses for this type of cell migration
in the body are in embryonic development and wound healing. This type of invasion is prominent
in melanoma, large cell lung cancer, epithelial prostate cancer, and most commonly in
squamous cell carcinoma (33).

III. Molecular Machinery of Mesenchymal and Amoeboid Invasion
3.1: The Rho Family of GTPases
The Rho family of GTPases, which is a subfamily of the Ras superfamily, is a class of
small signaling G proteins (~21 kDa) known to heavily regulate intracellular actin dynamics and
have roles in multiple functions including cell motility, cytoskeletal management, wound healing,
cytokinesis, and organelle development (23). In mammals, over 20 members of this family have
been identified, but the most common and extensively characterized are Rac1, RhoA, and cdc42
(34). These proteins have been found to affect formation of lamellipodia/membrane ruffling,
stress fibers, and filopodia, respectively (23).
GTPases act as signaling switches by first binding guanosine triphosphate (GTP) and
then binding various downstream effectors (24). To deactivate the signal, GTP is hydrolyzed by
the protein into guanosine diphosphate (GDP), and the GTPase dissociates from the effector.
These GTP- and GDP-bound states of GTPases are regulated by two different protein families:
guanine nucleotide exchange factors (GEFs) which prime GTPases through facilitating the
switching out of GDP for GTP, and GTPase-activating proteins (GAPs) which turn off GTPases
through stimulation of their GTPase enzyme activity and subsequent hydrolysis of GTP to GDP
(34).
The mesenchymal and amoeboid pathways exhibit a competing relationship between the
activities of Rac1 and RhoA GTPases (35, 36). Mesenchymal phenotype has been classified as
6

having high activity of Rac1, while amoeboid phenotype has high activity of RhoA (36). Both
Rac1 and RhoA have their own subfamilies within the greater Rho family of GTPases, but Rac1
and RhoA have been identified as the most important and main contributors to the
mesenchymal/amoeboid motilities. The Rac-related subfamily includes Rac1, Rac2, and Rac3,
which all share 80% sequence identity (23). While Rac1 is ubiquitously expressed throughout
the body, Rac2 is only expressed in hematopoietic cells, where it has a role in NADPH oxidase
activation and formation of reactive oxygen species (ROS) (23). Rac3 is expressed highly in
brain, where it is thought to have a role in neuronal differentiation (37). The Rho-related
subfamily, sharing 85% identity, consists of RhoA, RhoB, and RhoC (23, 38). All 3 members
have been found to be ubiquitously expressed, but their subcellular localization varies (34).
RhoA and RhoC localize to the plasma membrane, while RhoB localizes to endosomal
membranes (39). This is thought to be due to their differences in 15 amino acids at the Cterminal, where they exhibit the highest contrast (23, 34). RhoA and RhoC are both activated at
the cell edge, playing roles in actomyosin contractility and cell movement (23). RhoC has also
been implicated in promoting directional polarized migration, and appears to become activated
slightly before RhoA (39, 40) In contrast, the localization of RhoB to endosomes has shown it
to have a role in intracellular trafficking, receptor-mediated angiogenesis, and cell survival (41).

3.2: Proteins of the Mesenchymal Pathway
Rac1 GTPase has been proven vital to the function of the mesenchymal pathway. Rac1
binds and activates the WAVE regulatory complex (Wiskott-Aldrich syndrome protein family
verprolin-homologous protein) (42). This activation by Rac1 causes a conformational change
that releases inhibition on the VCA (verprolin, cofilin, acidic) domain of WASP family proteins
like WAVE, allowing their VCA domain to bind and stabilize a small protein called Arp2/3 (actinrelated protein 2/3). Arp2/3, which physically resembles a cluster of monomeric globular actin,
7

acts as a seed for the polymerization of new actin filaments (42). This polymerization aids in the
formation of actin-rich lamellipodia and invadopodia structures. Lamellipodia are broad sheetlike membrane protrusions at the leading edge of the cell membrane, given structure by a dense
and dynamic network of actin filaments, which assist in cell motility and mechanosensing of
ECM rigidity (43). Invadopodia are more specialized actin-based protrusion structures –
necessary for the degradation of ECM components and the basement membrane, subsequently
promoting invasion and metastasis (44).
Invadopodia formation localizes the activation and secretion of matrix metalloproteinases
(MMPs), which are very important for the mesenchymal phenotype. This family of zincdependent proteolytic enzymes modify and degrade components of the ECM to create tunnels
and pathways for cells to invade (45, 46). The cleavage of ECM proteins by MMPs can also
contribute to invasion through the uncovering and release of new binding sites in the ECM that
can stimulate multiple signaling pathways such as proliferation, migration, or angiogenesis (47,
48). In addition to their path-clearing capacity, MMPs can also dissociate cell-ECM and cell-cell
junction connections, leading to the release of individual cells from epithelial sheets and
promoting invasion (46, 49, 50). Over 20 members of the MMP family exist in humans, which
can be further classified into subgroups based on their main substrates or their structure. These
include collagenases (MMP-1, MMP-8, MMP-13, MMP-18), which cleave collagens, gelatinases
(MMP-2, MMP-9), which degrade gelatin/denatured collagens, stromelysins (MMP-3, MMP-10,
MMP-11) and matrilysins (MMP-7), which target a wide variety of other non-collagen ECM
proteins, and membrane-type MMPs (MT1-MMP/MMP-14, MMP-15, MMP-16, MMP-17, MMP24, MMP-25), which are transmembrane MMPs that express on the cell surface instead of being
secreted (45, 46). Multiple specific MMPs have been found to have important roles and influence
in the progression of breast cancer. For example, MMP-3 and MMP-7 both target E-cadherin, a
transmembrane protein important for cell-cell junctions, causing disruption of cell aggregation,
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releasing an active cleaved signaling molecule that stimulates invasion itself, and promoting
EMT in mammary epithelial cells (51, 52). Furthermore, targeting of proteins such as protease
activated receptor 1 (PAR-1) and P-cadherin by MMP-1 or MMP-2 has been shown to enhance
invasion of breast cancer cells (53, 54). Additionally, the membrane-bound MT1-MMP has been
linked to breast cancer invasion, seemingly through its processing of alpha-V integrin (55, 56).
The importance of this link between MMP activity and the mesenchymal phenotype cannot be
understated.
In order for Rac1 to carry out its role in regulating lamellipodia and invadopodia formation
and subsequent MMP activation, it must first be activated itself by a GEF protein. Multiple GEFs
for Rac1 GTPase such as VAV2, DOCK180, DEF6, ECT2, and DOCK8 have been identified in
various tissues (57-61). In melanoma cell lines, it has been shown that Rac1 is activated by the
Rac1 GEF DOCK3 (dedicator of cytokinesis 3), which is recruited to cell membranes through
interaction with a scaffold protein called NEDD9 (neural precursor cell expressed
developmentally down-regulated 9), also commonly referred to as Cas-L or HEF1 (human
enhancer of filamentation 1) (35, 36). NEDD9 is a member of the Crk-associated substrate (Cas)
family of proteins, which also includes p130cas/BCAR1, EfS/Sin1, and CASS4/HEPL (62).
NEDD9 is known to participate in migration and proliferation pathways (12, 25, 63) and is
commonly overexpressed in many human cancers, including both melanoma (64) and breast
(12). Scaffold proteins like NEDD9 do not possess enzymatic activity of their own, but instead
act as binding partners to bring multiple proteins together in a complex. It was shown in
melanoma that large focal adhesion signaling complexes form in mesenchymal cells consisting
of multiple proteins including integrin β3, Src, FAK (focal adhesion kinase), NEDD9, and DOCK3
(35). These focal adhesion complexes act as signaling hubs mediating mechanical crosstalk
between the extracellular matrix and the inside of the cell. Mesenchymal cells are known to
possess larger, more mature focal adhesions which recruit multiple adaptor proteins such as
9

talin, paxillin, and vinculin. FA maturation leads to increased activation/phosphorylation of FAK
and paxillin, and can occasionally culminate in the formation of very long fibrillary adhesions
(65).
Other proteins have been linked to the success of mesenchymal movement as well.
Vascular endothelial growth factor (VEGF), a signaling protein which regulates vasculogenesis
and angiogenesis, has been found to play a role in tumor growth and metastasis (66).
Expression of the VEGF189 isoform, which binds at the cell membrane and interacts with the
ECM, promotes mesenchymal phenotype and invasion (67). Secretion of the soluble isoform
VEGF165 has been linked to amoeboid phenotype and has been found to support blood stream
extravasation and metastasis to a greater degree than VEGF189 (67, 68). Activity of VEGF189
is enhanced through cleavage by proteases such as MMPs and urokinase plasminogen activator
(69). Subsequently, expression of the urokinase plasminogen activator receptor (uPAR) has
also been implicated in supporting mesenchymal invasion (70).
Additionally, the cyclin-dependent kinase inhibitor 1B (p27Kip1) has been found to support
mesenchymal motility and suppression of amoeboid signaling in multiple cells including
macrophages (21), breast cancer (71), hepatocellular carcinoma (72), and melanoma (73). This
role is dependent upon the transfer of p27 from the nucleus to the cytoplasm, where it colocalizes with F-actin to help mediate Rac-driven migration (71-73). The exact substrates and
mechanism by which p27 promotes Rac activation are not fully understood, however it has been
shown that the C-terminal of p27 can bind RhoA and inhibit its activation through physical
blockage of Rho-GEF interactions (74). This is an important example of how these pathways
can exhibit control upon each other in order to downregulate the opposite pathway – this will be
further detailed in Chapter 3.5.
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3.3: NEDD9 Promotes Mesenchymal Movement through an Additional AURKA-Driven
Signaling Pathway
It has been previously shown that NEDD9 contributes to activation and stabilization of
the enzyme AURKA (75, 76), a serine/threonine kinase that is also overexpressed in a majority
of human cancers including melanoma and breast (77-80). AURKA has been shown to
phosphorylate the consensus sequence [R/K/N]-R-X-[S/T]-B, where B represents a hydrophobic
amino acid (81). It is known that AURKA has a role in cell cycle and mitosis as a crucial enzyme
in the formation of the mitotic spindle at the centrosome, linking it to cell proliferation processes
(82). The common overexpression of this kinase in breast cancer correlates with poor survival
in breast cancer patients (83). Nevertheless, the mechanisms of AURKA action on different
stages of metastasis and particularly on invasion are currently unknown.
AURKA has been previously shown to phosphorylate and activate the histone
deacetylase HDAC6 (76). This activation of HDAC6 leads to deacetylation and increased activity
of cortactin, an actin-binding scaffolding protein that contributes to actin branching and
polymerization (84). Cortactin binds and stimulates Arp2/3 with its N-terminal region while
simultaneously binding the sides of filamentous actin with its actin-binding repeat region (42).
Interaction of Arp2/3 with Wiscott-Aldrich syndrome proteins like WASP or WAVE, which bind
the SH3 domain of cortactin, can bring further stimulation to the activity and stability of Arp2/3
(85). Additionally, Arpc1b, a component of Arp2/3, has been recently reported to be a direct
substrate of AURKA, which may also help to trigger its activity (86). Once Arp2/3 is active,
polymerization of branched actin from the sides of filaments can be formed, constructing a
branched actin meshwork. This polymerization of monomeric actin as a result of cortactin,
Arp2/3, and WASP family members is vital to the formation of lamellipodia and invadopodia
structures in promoting mesenchymal movement.
These additional signaling relationships as a result of NEDD9 expression suggest that in
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addition to its role in activating the Rac1 signaling cascade, NEDD9 can also promote
mesenchymal motility through a second cascade of interactions involving NEDD9, AURKA, and
CTTN - potentially making NEDD9 a critical hub of invasive stimulation that may mark it as a
prime therapeutic target.

3.4: Proteins of the Amoeboid Pathway
Similar to Rac1’s role in driving mesenchymal movement, the GTPase RhoA acts in a
comparative manner to support the amoeboid signaling cascade. Multiple GEF proteins such as
p114RhoGEF or Net1 have been found to activate RhoA (87-90). In breast cancer cells, it was
shown that the cytokine CXCL12 helps support RhoA activation through its receptor CXCR4 and
the GEF Net1 (90). Once active, RhoA binds and stimulates the Rho kinase ROCK (rhoassociated, coiled-coil containing protein kinase) (91). ROCK belongs to the AGC family of
serine-threonine kinases and mainly functions in regulation of cytoskeletal proteins (92, 93).
Amino acid consensus sequences for ROCK-targeted phosphorylation are [R/K]-X-[S/T] and
[R/K]-X-X-[S/T], where the X amino acids can vary (94). The main target of ROCK in driving
amoeboid migration is phosphorylation of MLC (myosin II light chain), thereby increasing
actomyosin contractility of the cell membrane (92). ROCK can also phosphorylate and activate
LIMK1, another protein kinase that functions to inactivate cofilin, an actin severing and
depolymerization factor (95). LIMK1 was found to be critical for MAT in fibrosarcoma cells (96).
Additional targets of RhoA include the formin Dia2 – interaction and colocalization between Dia2
and its partner DIP (diaphanous interacting protein) have been found to be necessary for the
formation of membrane blebbing areas in breast cancer cells, supporting amoeboid migration
(90, 97). Another formin-related protein, FMNL2, has also been found to support amoeboid
movement in breast cancer cells, however interestingly is more specific for RhoC GTPase
interaction than RhoA (98). RhoC has also been shown to interact with FMNL3 (39).
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In contrast to mesenchymal cells, amoeboid cells possess less mature focal adhesions
and instead have many smaller, weaker nascent adhesions. These adhesions contain some of
the same adaptor proteins as mature focal adhesions such as talin and paxillin, however the
activation/phosphorylation of paxillin is decreased. Vinculin, a more mature FA marker, is less
present in nascent adhesions. Loss of ERalpha, one of the hallmarks of TNBC, has been
associated with a decrease in vinculin expression and an increase in amoeboid invasion and
breast cancer metastasis (99).
The protein ezrin, a crosslinker between the plasma membrane and the actin
cytoskeleton, has been hypothesized to have an important role in focusing the directionality of
amoeboid movement. In amoeboid-moving melanoma cells, ezrin was found to localize to the
cell rear, where it tightly binds the plasma membrane and seems to locally hinder bleb formation
(100). This model suggests that a tiny hydrostatic pressure released by bleb formations in the
front of the cell is able to create a small polarized motile force, thus pulling the cell forward in
the direction of bleb growth.
Several other proteins have been implicated in supporting the amoeboid pathway or MAT
in different cancer cell lines. In melanoma, TGF-beta stimulation was found to promote
amoeboid phenotype along with increased expression of associated signaling transducers
SMAD2, SMAD3, and CITED1 (101). Hypoxic conditions and expression of HIF-1alpha have
been found to transition the collective movement of breast carcinoma and head and neck
squamous cell carcinoma (HNSCC) cells to amoeboid migration (102). Other proteins whose
expression has been reported to strengthen amoeboid phenotype include PKC-alpha (103),
ACTN4 (104), EphA2 receptor tyrosine kinase (105), CD99 (106), NG2 (107), annexin II (108),
transcription factors NANOG and Oct-4 (109), and collagen receptor Endo180 (110). The exact
mechanisms for how many of these proteins help contribute to amoeboid phenotype are still
unclear.
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3.5: Regulation between Mesenchymal and Amoeboid Pathways
To balance the competing relationship between mesenchymal and amoeboid
phenotypes, various regulators have been shown to be utilized by each pathway to inhibit the
competing signaling processes (35, 36). Upregulation of the microRNA let-7i by the amoeboid
pathway has been shown to disrupt Rac1 signaling through suppressing expression of the
mesenchymal proteins NEDD9 and DOCK3 in HNSCC cell lines (111, 112). Let-7i has also been
found to repress expression of AURKA (113). As a counter, the transcriptional regulator Twist1,
a known EMT inducer, has been shown to suppress expression of let-7i through the oncogene
BMI1 (111-113). Another microRNA, miR-200c, has also been found to be upregulated by
amoeboid signaling. Increased ratio of miR-200c to its other miR-200 family member miR-200a
was found to induce MAT through inhibition of expression of cytoskeletal regulatory proteins
MARCKS, FHOD1, and PPM1F in melanoma and breast cancer cells (114, 115). Besides
microRNA, the amoeboid pathway is also capable of disrupting Rac1 signaling through inhibition
of p27Kip1 expression via ROCK-dependent stimulation of the ERK pathway (116, 117). In
addition, the amoeboid pathway can upregulate Rac1 GAP proteins such as ARHGAP22 in
melanoma (36) or FilGAP in multiple cancers to hinder Rac1 activity (118-120). Similarly, the
mesenchymal pathway can upregulate RhoA GAPs such as RASAL2 in astrocytomas to
downregulate RhoA activity (121).
In melanoma, the mesenchymal pathway has been found to counter the amoeboid
pathway through activation of Src by NEDD9, which phosphorylates and inhibits ROCK activity
(35), and also through WAVE expression, although this exact mechanism is less well defined. It
is hypothesized that an interactor of WAVE, Hem-1 (hematopoietic protein 1), may potentially
interact with Rho GAPs or myosin phosphatase (36). Myosin phosphatase negatively controls
amoeboid movement through dephosphorylation of MLC, and is known to be regulated through
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direct phosphorylation by ROCK itself and also through Wnt signaling pathways (94, 122). Wnt
signaling proteins such as WNT5A are known activators of the RhoA/ROCK cascade and have
been found to influence the amoeboid pathway (123, 124). In hepatocarcinoma cells, MMP
inducer CD147 has been found to support the mesenchymal pathway through binding and
inhibition of phosphorylation of annexin II, a phospholipid binding protein that is upregulated in
amoeboid phenotype (61, 108). Together, this data illustrates the intense checks and balances
that the mesenchymal and amoeboid pathways can enforce on each other to keep the opposite
signaling networks suppressed.

IV. Treatment of Breast Cancer Invasion and Metastasis
4.1: Targeting the Mesenchymal Pathway
Matrix metalloproteinases are an attractive target for stoppage of mesenchymal
movement. Without these matrix degrading enzymes, tumor cells will encounter difficulty in
being able to create tunnels and invade through the ECM. Whether through techniques such
as siRNA knockdown or usage of MMP-targeting chemical compounds or small molecules,
MMP inhibitors (MMPI) are a commonly used technique for targeting of cell invasion. Numerous
MMPI which target many MMP proteins (broad spectrum) or a specific MMP protein have been
designed and utilized over the years with varying degrees of success (125). Some MMPI have
made it to clinical trials such as batimastat (phase I/II) (126-128) and marimastat (phase III)
(129), but have not gained further traction due to different issues such as bioavailability, toxicity,
or minimal effects on survival (130, 131). The only MMPI currently approved by the Food and
Drug Administration is doxycycline, which is used as a treatment for periodontal disease (132).
The difference in success between why some tumors respond to MMPIs better than others may
be due to the potential of mixed cancer cell populations of both mesenchymal and amoeboid
phenotypes and some populations leaning more heavily toward amoeboid, where MMP
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inhibitors would have less effect. Nevertheless, inhibition of MMPs in in vitro or in vivo animal
models has been shown to decrease Rac1 activity/cell elongation, increase RhoA activity/cell
roundedness, and subsequently decrease cell invasion (70, 88, 105). This has been combined
with targeting of uPAR in prostate and melanoma cancer cells, yielding exacerbated effects
(70).
Multiple other proteins have been targeted for inhibition of the mesenchymal pathway.
Depletion of NEDD9 has been associated with a decrease in overall invasion and metastasis,
as well as switching cells to a more amoeboid phenotype (133). This also has been shown to
hinder the activation and secretion of MMPs (134, 135). Administration of the AURKA inhibitor
MLN8237 (alisertib) decreases tumor growth and metastasis of breast cancer (136).
An alternative option to “inhibit” the mesenchymal pathway could be to promote activation
of the amoeboid pathway, thereby downregulating mesenchymal signaling. Use of calpeptin, a
RhoA activator, has been used to switch mesenchymal melanoma cells to amoeboid migration,
but with minimal effect on invasion (105).

4.2: Targeting the Amoeboid Pathway
Due to its vital role in regulation of actomyosin contractility and cytoskeletal
rearrangement, the Rho kinase ROCK has become a popular drug target of the amoeboid
pathway. Several ROCK inhibitor compounds have been designed – some of the earliest and
most commonly tested being Y-27632 (137) and H-1152 (138). No ROCK inhibitors have yet
been approved for human use in the United States by the Food and Drug Administration,
however the compound fasudil has been permitted for clinical treatment of cerebral
vasospasm in Japan and China (139, 140). Additionally, a derivative of fasudil called ripasudil
has recently been approved for treatment of glaucoma in Japan (141). Despite no ROCK
inhibitors being clinically available for treatment of human cancer, they have still shown
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promise against blocking invasion and metastasis of cancer cell lines in vitro and in animal
models (92). A newly developed compound, AT13148, which blocks multiple AGC kinases
including ROCK, has shown substantial benefit against melanoma metastasis in mice (142).
A phase I clinical trial for the inhibitor AT13148 is currently ongoing for evaluation against
multiple cancer types with results expected to conclude this year (ClinicalTrials.gov identifier
NCT01585701) (140).
Knockdown or inhibition of various amoeboid pathway components besides ROCK have
yielded promising results in hindering cell invasion and metastasis. The RhoA GEF
p114RhoGEF was targeted in MDA-MB-231 TNBC cells and caused a decrease in migration,
a decrease in RhoA activity, and an increase in Rac1 activity (87). Targeting of other RhoA
GEFs such as Net1 has yielded similar results with decreases in BC cell migration and
increases in elongated mesenchymal phenotype/MMP activity (89). PKCalpha inhibition
switched melanoma and BC cells from rounded to elongated phenotype and decreased cell
invasion, whereas activation of PKCalpha increased the percent of rounded cells, yet yielded
no additional increase in invasion (103). ACTN4, a crosslinker of actin filaments at adherens
junctions and focal adhesions, has been found to support rounded amoeboid morphology.
Knockdown of ACTN4 decreased melanoma cell invasion, increased the persistence of FAs
and switched cells to elongated phenotype (104). Additionally, chondramide, a naturally
occurring compound that targets the actin cytoskeleton, has been shown to hinder amoeboid
movement and breast cancer metastasis through inhibition of cell contractility (143).

4.3: Dual Pathway Targeting
Due to the fact that cancer cells have the ability to utilize both of these cell motility
methods, the ideal treatment option may be one that hinders both pathways simultaneously. In
doing so, the cell will not be able to invade even if it switches its phenotype to the opposite
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pathway. This theory has been previously attempted in literature using combinations such as
MMP and ROCK inhibitors in pancreatic and glioblastoma cancer cell lines (88, 144), Rac1
siRNA with ROCK inhibitors in melanoma and glioblastoma cell lines (36, 145), and DOCK3
siRNA or NEDD9 siRNA with ROCK inhibitors in melanoma cell lines (36), and MMP inhibitor
and Rho GEF siRNA in breast cancer cell lines (87). Use of this dual targeting strategy showed
a promising synergistic decrease in cell invasion upon concurrent suppression of mesenchymal
and amoeboid processes.

4.4: Comparisons of Mouse Models
In order to assess the viability of such a treatment strategy for clinical trials, an in vivo
mouse model offers a safe alternative to human patients and is a prevalent representation for
the study of cancer. Multiple different types of models exist, including genetically-engineered
mouse models (GEM), xenograft models (XG), and patient-derived xenograft models (PDX), all
offering their own advantages and disadvantages (146). GEMs allow for the genome of a mouse
population to be altered to either express, delete, or mutate some target gene of interest. NEDD9
knockout animals have been previously made and are viable from birth (25). These models allow
for the studying of tumor growth from the early stages of mouse development, but applicability
of this knowledge is limited due to the growth of a murine tumor in a murine microenvironment,
which may not correlate well with the development of human tumors. It is also a slow, time
consuming, and expensive method.
Xenograft models (XG) are cheaper and faster to do, and they allow for the growth of a
human tumor in a mouse using human cancer cell lines. However, this tumor of human cancer
cells is still grown within a murine microenvironment, and in order for the tumor to propagate,
the mouse host must lack a functional immune system, thus limiting our understanding of
immune response to the tumor. PDX models are similar to XG models in that they also have
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similar concerns using a murine microenvironment and immune-compromised mice, however
they differ by implantation of an actual piece of tumor tissue from a human patient into a mouse
rather than utilization of immortalized cell lines. Unlike a cell line, this tumor tissue was originally
grown in a human microenvironment and is a heterogeneous cell population, making this model
one of the best systems to study human tumor growth, metastasis, and anti-cancer drug
response. Disadvantages of PDX models include the scarcity and expensiveness of their source
material, which must be isolated from human patient tumors, and the fact that they are less
easily manipulated. Normal XG models do not have these issues, since cell lines are readily
available and much simpler to engineer or alter for experimental procedures.

V. Hypothesis
It is currently unknown whether previous findings of NEDD9 having a pivotal role in the
switch between mesenchymal/amoeboid migration processes in melanoma could be applied to
other cancers, notably breast cancer (35, 36). The downstream targets of the NEDD9-dependent
signaling pathway involved in regulation of mesenchymal migration in breast cancer are also
currently unknown. The central hypothesis of this project was that simultaneous inhibition of key
components of both the mesenchymal and amoeboid invasion pathways, including NEDD9
protein expression, will have a synergistic effect limiting breast cancer migration and metastasis
in vitro and in vivo.
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Abstract
Commonly upregulated in human cancers, the scaffolding protein NEDD9/HEF1 is a known
regulator of mesenchymal migration and cancer cell plasticity. However, the functional role of NEDD9
as a regulator of different migration/invasion modes in the context of breast cancer metastasis is
currently unknown. Here, it is reported that NEDD9 is necessary for both mesenchymal and amoeboid
individual cell migration/invasion in triple-negative breast cancer (TNBC). NEDD9 deficiency results in
acquisition of the amoeboid morphology, but severely limits all types of cell motility. Mechanistically,
NEDD9 promotes mesenchymal migration via VAV2-dependent Rac1 activation, and depletion of
VAV2 impairs the ability of NEDD9 to activate Rac1. Additionally, NEDD9 supports a mesenchymal
phenotype through stimulating polymerization of actin via promoting CTTN phosphorylation in an
AURKA-dependent manner. Interestingly, an increase in RhoA activity in NEDD9-depleted cells does
not facilitate a switch to functional amoeboid motility, indicating a role of NEDD9 in the regulation of
downstream RhoA signaling effectors. Simultaneous depletion of NEDD9 or inhibition of AURKA in
combination with inhibition of the amoeboid driver ROCK results in an additional decrease in cancer
cell migration/invasion. Finally, we confirmed that a dual targeting strategy is a viable and efficient
therapeutic approach to hinder the metastasis of breast cancer in xenograft models, showcasing the
important need for further clinical evaluation of this regimen in order to impede the spread of disease
and improve patient survival.

Implications: This study provides new insight into the therapeutic benefit of combining NEDD9
depletion with ROCK inhibition to reduce tumor cell dissemination and discovers a new regulatory role
of NEDD9 in the modulation of VAV2-dependent activation of Rac1 and actin polymerization.
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Introduction
Scaffolding protein NEDD9/HEF1, commonly overexpressed in many human cancers, is a
critical regulator of cancer cell migration (1, 2). Cancer cells are capable of migrating either collectively
or individually (3-5). In collective migration, cells retain most of their epithelial characteristics including
cell-cell adhesions and invade as a sheet (6), thus enabling regional invasion and lymphatic-based
metastasis. Alternatively, individual migration is distinguished by a loss of cell-cell adhesions and the
ability to invade via two different methods known as mesenchymal and amoeboid (7-9), leading to
blood-borne metastasis. Depending on extracellular matrix (ECM) composition and rigidity of the
tumor microenvironment, the mesenchymal and amoeboid modes can be used interchangeably by
the same cell population (3, 8). Initial nascent adhesions are highly present in amoeboid cells,
consisting of integrin, talin, and non-phosphorylated paxillin. The recruitment of vinculin and FAK/Src
complex and activation/phosphorylation of paxillin and FAK is indicative of focal adhesion (FA)
maturation, which can culminate in formation of very elongated fibrillar adhesions (10), which are often
found in mesenchymal cells.
Elevated expression of NEDD9 protein is required for individual mesenchymal migration of
diverse tumor cells (1, 11, 12). Mesenchymal migration is characterized by an elongated cell
morphology, multiple focal/3D adhesions, and the ability to degrade ECM by matrix metalloproteinases
(MMPs) (7, 13), creating a path through the basement membrane/tissue. A master regulator of
mesenchymal migration, Rac1 GTPase, is activated by a number of guanine nucleotide exchange
factors (GEFs), including melanoma-specific DOCK3 (14), which is recruited/activated by NEDD9
(15). Rac1 activates the WAVE regulatory complex leading to polymerization of actin filaments (16).
We have previously shown that NEDD9 also activates and stabilizes Aurora A kinase (AURKA) (17),
which phosphorylates and activates histone deacetylase HDAC6 (18), leading to deacetylation and
subsequent increased activity of the actin branching/stabilizing protein cortactin (CTTN) (19), which is
necessary for lamellipodia and invadopodia formation - structures that define mesenchymal invasion.
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Rac1-driven mesenchymal migration runs counter to the corresponding RhoA GTPase and
ROCKII kinase-driven amoeboid pathway. Amoeboid migration is characterized by a rounder cell
morphology, small/weak adhesions, and increased cell contractility (7, 20). This type of locomotion
does not typically rely on matrix degradation, and instead slightly deforms the cell shape to squeeze
through pre-existing gaps in the ECM (21). Because of this, amoeboid movement is more suited for
invasion through less dense and more elastic matrices such as collagens. Mechanistically, RhoA binds
and activates ROCKII which phosphorylates myosin II light chain (MLC2), thus increasing actomyosin
contractility and amoeboid invasion. NEDD9 contributes to downregulation of the amoeboid pathway
through binding/activating Src kinase, leading to phosphorylation/inhibition of ROCKII (11).
The impact of NEDD9 on collective tumor cell invasion has not been explored. However,
collective migration of lymphocytes in NEDD9 knockout mice was shown to be significantly reduced
(22), and neuronal tube formation in mouse and chick embryos was inhibited upon NEDD9 depletion
(23). We have shown that a decrease in NEDD9 expression leads to significant deficiency in activation
of MMPs (24, 25), suggesting a deficiency of these cells to create tunnels through the matrix.
Since individual tumor cells are capable of utilizing either one of these modes of movement,
simultaneous targeting of both pathways may provide significant clinical benefit against metastatic
cancers (14, 26). In this current study, we define the molecular mechanisms of NEDD9-dependent
Rac1 activation and the efficacy of combined inhibition of both types of cell movement to hinder the
metastasis of triple negative breast cancer (TNBC).
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Materials and Methods
Cell lines, RNAs, and plasmids
TNBC cell lines MDA-MB-231LN (Caliper); Hs578T, HCC1143, BT549, HCC1395 (American
Type Culture Collection); and SUM159 (gift from Dr. Boerner, Karmanos Cancer Institute) were
authenticated and propagated for less than 6 months. si/sh/sgRNAs and plasmids used in this study
are described in detail in the Supplementary Materials and Methods. The plasmids/RNAs were
introduced via nucleofection (Amaxa) according to manufacturer’s recommendation or virus infection
(293T packaging cells, LifeTechnologies) as previously described (24).
Recombinant protein production
Recombinant AURKA (19), wild type and N/C-term CTTN (27), and GST and GST-PBD
proteins were produced as previously described (28).
Cell morphology analysis
104 cells were plated on 2D or in 3D 1.5mg/ml collagen (Advanced BioMatrix) or 4mg/ml
Matrigel (Corning) as previously described (30). Cells were treated with 50 or 100µM Y-27632
(ApexBio) where indicated. Cells were brightfield imaged on a Leica DM/IL microscope. Cell
elongation was measured as a function of cell length divided by cell width (ImageJ software/NIH).
Western blotting
Western blots were performed as previously described (24). Further details and a list of
antibodies used can be found in the Supplemental Material and Methods.
Immunofluorescence
The edges of 18mm round glass coverslips (Fisher) were coated with a Super-HT-PAP-PEN
hydrophobic slide marker and coated inside with 0.01% poly-L-lysine (Electron Microscopy Sciences).
For 3D matrix embedding, 2.5x104 cells suspended in 200µl of 1.5mg/ml collagen-I or 4mg/ml Matrigel
plug were loaded on the coverslips. Coverslips were placed into a 12-well plate and incubated in a
37°C humid chamber during polymerization. Full media was added, and the cells were allowed to
35

acclimate to the matrix for 48 hours. Fixation and immunofluorescence staining was carried out as
previously described (29). The list of used antibodies and quantification details are provided in the
Supplemental Material and Methods.
Collagen gel contraction assay
1x106 cells per sample were suspended in 1.5mg/ml collagen and inserted into a well in a 12well plate. Triplicate wells were included per cell line and a well with no cells was included as control.
Once polymerized, media was placed on top of the collagen plug. After 24 hours, the collagen plugs
were detached from the walls and bottom of the well. Gels were imaged (Syngene/G-Box) every 15
minutes for the first few hours followed by hourly images up to 24 hours. Gel area was measured by
manual outlining of the collagen plugs and analyzed in ImageJ.
Radioactive kinase assays
2.5μCi of [γ-32P]-ATP (Perkin Elmer) suspended in kinase buffer (28) was added to recombinant
AURKA and/or CTTN (25-50ng) protein and incubated for 30 minutes at 30°C. Samples were then
subjected to gel electrophoresis and membrane transfer followed by X-ray film exposure for 2 hours
to visualize phosphorylation and western blotting to visualize total protein level.
Actin polymerization assays
Actin polymerization assays were carried out according to manufacturer’s recommendation
(Cytoskeleton). Recombinant AURKA (3mM), CTTN (75nM), Arp2/3 (50nM, Cytoskeleton) or WASPVCA domain (5µM, Cytoskeleton) suspended in magnesium/ATP cocktail were added to 5µM pyrenelabeled G-actin in a 96-well plate and actin polymerization was measured based on the increase of
fluorescence at excitation 365nm/emission 407nm every 30 seconds for 20 minutes at 30°C using a
GENios plate-reader (Tecan).
Cell kymography
Kymography analysis was carried out as previously described (19). In brief, cells were plated
on glass bottom dishes (Fisher Scientific) 48 hours after nucleofection with mCherry-LifeAct. Cells
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were then treated overnight with 100nM AURKA inhibitor MLN8237 (Selleckchem) and live-imaged
the next day every 45 seconds for 60 minutes. Kymograms were compiled from a perpendicular 1
pixel-width line from each frame on the same spot of the cell membrane.
Active Rac1 pulldown assays
Cells were nucleofected with the indicated plasmids/siRNAs and allowed to recover overnight,
followed by suspension of 1.5x105 cells in 450μl of 1.5mg/ml collagen-I or 4mg/ml Matrigel. In indicated
assays, cells were also treated overnight with 4µM EHop-016 (ApexBio). After 24 hours, cells were
lysed for 10 minutes on ice with 1X Rac1 lysis buffer as previously described (30). Lysates were spun
down at max speed for 12 minutes at 4°C and supernatants were added to Glutathione-4FastFlow
sepharose (GEHealthcare) loaded with GST or GST-PBD protein, rotating at 4°C for at least 1 hour.
Sepharose was then washed three times with lysis buffer, boiled in Laemmli buffer and subjected to
gel electrophoresis and western blotting.
Active Rac1 and RhoA G-LISA assays
G-LISA activation assays for Rac1 and RhoA were performed as recommended by the
manufacturer’s protocol (Cytoskeleton).
Immunoprecipitations of GEF proteins
pcDNA3.1-mRFP-NEDD9 and Rac1 GEF-expressing plasmids were co-transfected into 293T
cells using TurboFect (ThermoFisher) per manufacturer protocol. After 24 hours, cells were lysed with
PTY lysis buffer and processed as previously described (28). Lysates were precleared with proteinA/G-sepharose (GEHealthcare) for 1 hour at 4°C. Mouse IgG control/or anti-NEDD9 (2G9) proteinA/G sepharose, or anti-HA/anti-FLAG EZview-Red antibody (Sigma) were added to precleared lysates
for 12 hours rotating at 4°C. Beads were then washed three times with PTY buffer. To elute proteins
from the beads, 10% ammonia hydroxide was added for 15 seconds followed by speed-vacuum
centrifuge to remove ammonia hydroxide. Protein was then resuspended in Laemmli buffer for gel
electrophoresis and western blotting. The IP of CTTN is detailed in the Supplemental Materials and
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Methods.
Live-cell imaging of individual cell invasion
Cells treated with si/sgRNAs against NEDD9 or RhoA and/or overexpressing CA-RhoA and/or
treated with 50µM Y-27632 or 100nM MLN8237 for 24h were re-suspended in 1.5mg/ml collagen and
placed into 3D-Chemotaxis µ-slides (Ibidi) according to manufacturer protocol. Fetal bovine serum
was added to the left media reservoir to create a chemoattractant gradient. When used, Y-27632
and/or MLN8237 were also added to both reservoirs to keep the drugs present during the assay. Cells
were imaged every 15 minutes via DIC 10X objective on a Nikon Sweptfield/Eclipse/TE2000-E
confocal microscope for 23 hours. Time lapse images were imported into ImageJ software and
combined to form video files. Quantification methods are detailed in the Supplemental Materials and
Methods.
Live-cell imaging of collective cell invasion
1x105 cells in full medium were plated on top of 4-5mg/ml Matrigel-coated delta-T dishes
(Bioptechs). After 1 hour, the medium was removed and the cell layer was covered with more Matrigel.
After polymerizing for 30 minutes at 37°C, media was re-added. Live-cell imaging was conducted
every 10 minutes for 24 hours at 37°C via Nikon Sweptfield/Eclipse/TE2000-E confocal microscope
(20X objective). Time lapse images were imported into ImageJ software and combined to form video
files. Quantification methods are detailed in the Supplemental Materials and Methods.
Fluorescent imaging of collective cell invasion sandwich assay
Cells were pretreated overnight with 50µM Y-27632 or 100nM MLN8237, and 3x104 cells were
plated in 8-well chamber slides (ThermoFisher) coated with 150µl 4mg/ml Matrigel. After 1 hour, the
medium was removed and the cells covered with another 200µl Matrigel, followed by full media after
Matrigel polymerization. Cells were live imaged in 5µm Z-steps away from the cell seeding position at
72 hours using a Nikon Sweptfield/Eclipse/TE2000-E confocal microscope. Invasion was quantified
by total cell fluorescence intensity at the furthest distance cells reached (100µm). 3D invasion boxes
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were constructed using the Volume-Viewer plugin for ImageJ to show cell fluorescence signal
throughout the Matrigel from the seeding position.
Mouse xenograft study
Animals were housed in the WVU Animal Facility under pathogen-free conditions according to
an approved Institutional Animal Care and Use Committee protocol. 1x106 MDA-MB-231-luc2 cells
expressing doxycycline-inducible pTRIPZ-RFP-shControl or shNEDD9 (25) were suspended in
4mg/ml Matrigel (Trevigen) and injected into the mammary fat pad of 6-8-weeks old immunodeficient
female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice (Jackson Laboratory). Mice with mammary
tumors (150-200mm3) were pre-treated in neoadjuvant settings with 10mg/kg AURKA inhibitor
MLN8237 via oral gavage for 1 week (4 days on, 3 days off) as previously described to temporarily
halt metastasis, but continue mammary tumor growth (31). shRNA expression in tumor cells was
induced via introduction of doxycycline-containing food (Bio-Serv) in combination with vehicle or
10mg/kg Y-27632 which was administered by oral gavage for 3 weeks (4 days on, 3 days off). Tumor
growth and dissemination was evaluated weekly through in vivo whole-body bioluminescence imaging
(BLI) using an IVIS/Lumina-II system as previously described (17). After 3 weeks, lungs, mammary
tumors, and blood were collected for analysis. Paraffin-embedded lung sections were stained by
hematoxylin and eosin (H&E) and analyzed for the number of metastases per lung area by a
pathologist as previously described (17). Primary tumors were analyzed for NEDD9 expression by
western blot. Ten mice per both shRNA groups (further separated into 5 per drug group for a total of
20 mice) were used based on statistical analysis.
Quantification of circulating tumor cells
Submandibular mouse blood samples were collected into EDTA-coated tubes on ice to prevent
clotting. Erythrocytes were lysed and removed from blood via incubation with RBC lysis buffer
(eBioscience) according to manufacturer’s protocol. Cells were fixed in 2% paraformaldehyde for 10
minutes, followed by centrifugation at 500g for 5 minutes at 4°C, and resuspended in 1% BSA/PBS.
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Flow cytometry (FACS) was performed using a BD Biosciences/LSR Fortessa to count RFP-positive
circulating tumor cells in the blood samples. Final counts were normalized to initial primary tumor size
at week zero.
Statistical analysis
One-way ANOVA or student’s t-test statistical analyses were performed with GraphPad Prism
software where noted. p ≤ 0.05 was considered to be significant (*). Experimental values were reported
as the mean ± SEM (standard error of mean).
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Results
TNBC cell morphology changes upon NEDD9 and ROCK inhibition
Metastatic TNBC cell lines with primarily mesenchymal morphology (MDA-MB-231, BT549,
HCC1143, HCC1395, Hs578T and SUM159) were used to assess the role of NEDD9 in switching
cells from mesenchymal to amoeboid morphology. NEDD9 was depleted using previously
characterized siRNAs (17, 32) (Fig.1A) in a SMARTpool, and the changes in individual cell
morphology were monitored using live cell imaging microscopy when plated in 2D or suspended in 3D
matrix (collagen I or Matrigel).
In 2D, control (siCon) cells have well-defined elongated morphology, while NEDD9-depleted
(siNEDD9) cells show up to a 40% decrease in cell elongation (Fig.S1A-B) reflected by a decrease in
the ratio of cell length over cell width. In 3D matrix, the pore size is a critical determinant of cell
morphology and migration type (20). The average pore size of the collagen I matrix used was about
15 µm2 (Fig.S1C-D), which supports both amoeboid and mesenchymal movement (33). Alternatively,
the tightly-packed fibers that make up Matrigel are not conducive for amoeboid migration (<1 µm) and
are permissive primarily for matrix-degrading mesenchymal movement. Interestingly, when seeded in
either of these 3D scaffolds, siNEDD9 cells show acquisition of rounded amoeboid morphology and
up to a 50% decrease in cell elongation (Fig.1B-C), which is similar to 2D results.
Knockout of NEDD9 using sgRNAs and CRISPR/Cas9 technology led to similar changes in
morphology with less variability in cell elongation and showing an elongation ratio closer to 1,
indicating that they are more circular with similar cell length and width (Fig.S1E-F). This phenotype
was similar to cells overexpressing constitutively active RhoA GTPase (Fig.1D-F), suggesting RhoA
activity may be high in NEDD9 deficient cells. Importantly, almost all TNBC cells demonstrated
significant plasticity in their ability to not only be able to switch to amoeboid morphology, but also be
able to increase mesenchymal morphology, which was confirmed as control cells became further
elongated upon application of the well-characterized Rho kinase inhibitor, Y-27632 (Fig.1G-H).
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NEDD9 depletion leads to increased myosin light chain phosphorylation but decreased
contractility
Next, we tested if the acquisition of amoeboid morphology by NEDD9-deficient TNBC cells is
accompanied by a switch to amoeboid migration, which could potentially promote intra/extravasation
during metastasis of breast cancer. Actomyosin contractility and force-mediated remodeling of the
matrix is a signature of the amoeboid type of cell migration (34). A key driver of actomyosin contractility
is the Rho kinase ROCK, which phosphorylates myosin II light chain (MLC2) (35). In both collagen
and Matrigel, NEDD9 deficiency resulted in up to a threefold increase in pMLC2 (Fig.2A-D, Fig.S1J),
which co-localized with cortical actin around the cell membrane.
Interestingly, despite this increase in pMLC2 in NEDD9-depleted cells, there was a significant
decrease in the ability of the collective cell population to contract floating collagen gels (Fig.2E-F),
indicating that morphologically amoeboid NEDD9-depleted cells may not possess all of the
mechanistic properties of amoeboid cells. The inability of NEDD9-deficient cells to translate the
increased pMLC2 signaling to matrix deformation/contraction may be indicative of impaired adhesion
or actin dynamics connecting the internal and external forces of the cell.
NEDD9 depletion leads to a decrease in mature focal adhesion dynamics
Mature, large focal adhesions have been associated with the mesenchymal phenotype,
whereas a decrease in size and maturity has been linked to amoeboid morphology (36, 37). Staining
for phospho-FAK (pFAKY397) or phospho-paxillin (pPaxillinY31) has been commonly used to label
mature focal adhesions (37, 38). Immunofluorescence analysis shows up to a twofold decrease in the
number of adhesions positive for pFAKY397 and pPaxillinY31 upon NEDD9 depletion (Fig.2G-J, S1GJ), indicating a critical role of NEDD9 in adhesion maturation. The decrease in FAK and paxillin
phosphorylation was further confirmed by western blot in multiple breast cancer cell lines (Fig.2K-M,
S2). NEDD9 deficiency trended toward a decrease in the number of adhesions containing the more
mature/stable focal adhesion marker vinculin (39), which would be concurrent with amoeboid
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phenotype, however the length of many of these adhesions was increased compared to control,
suggesting the stabilization of fibrillar adhesions (Fig.S3). Nevertheless, NEDD9-depleted cells also
had an increase in the total number of small adhesions that contained talin (Fig.S4), which is one of
the first proteins recruited to focal contacts/adhesions (39). This indicates that there is an increase in
small, weak nascent adhesions and a decrease in mature adhesions, which is concurrent with
amoeboid phenotype (40). This may suggest that NEDD9 is not needed for adhesion initiation but is
required for fibrillary adhesion disassembly. Such duality may potentially affect both mesenchymal
and amoeboid adhesion dynamics.
NEDD9 regulates AURKA-driven phosphorylation of CTTN and stability of actin filaments
Amoeboid morphology is characterized by a decrease in filamentous actin polymerization while
the mesenchymal elongated shape relies on an increase in filamentous actin (7). Previously, we have
shown that NEDD9 binds and activates AURKA and the actin stabilizing protein CTTN, which results
in an increase in actin polymerization and stabilization of lamellar protrusions and invadopodia (19).
Here we show that AURKA directly phosphorylates CTTN (Fig.3A) at the (C-terminus 350-546aa)
(Fig.3B, S5). To assess the impact of this phosphorylation on actin dynamics, an in vitro actin
polymerization assay was carried out using recombinant AURKA and CTTN proteins. Incubation of
AURKA with CTTN resulted in a significant increase in the actin polymerization rate (Fig.3C)
compared to CTTN without AURKA. AURKA alone or in combination with Arp2/3 and WASP did not
significantly affect actin polymerization, indicating that CTTN is the major substrate of AURKA in this
assay. Moreover, kymography analysis of mCherry-LifeAct-expressing cells shows that the inhibition
of AURKA results in a complete blockade of lamellar protrusions (Fig.3D-F), indicating that AURKA
has a key role in cellular actin dynamics.
NEDD9 depletion decreases Rac1 activity in breast cancer cells
Rac1 GTPase has been shown to be one of the key drivers of mesenchymal
migration/morphology. To measure Rac1 activity in cells grown in either 3D collagen or Matrigel, GST43

tagged PBD (PAK p21 binding domain) protein was used to specifically pull down Rac1-GTP. Cells
overexpressing dominant negative Rac1 (DN) or constitutively active Rac1 (CA) were used as controls
(Fig.S6A). NEDD9 depletion resulted in a significant decrease in the amount of active Rac1 in cells
grown in both scaffolds (Fig.4A-B). This was consistent when repeated in two other mesenchymal
breast cancer cell lines as well, Hs578T and HCC1143 (Fig.S6B-C). As a complementary approach,
Rac1 G-LISA assays (41) were used to evaluate the effect of NEDD9 depletion. Similarly to the active
Rac1 pulldown assay, Rac1 G-LISA shows a decrease in the amount of active Rac1 (Fig.4B,
Fig.S6D). Additionally, the RhoA G-LISA shows an increase in the amount of active RhoA, which is
concurrent with amoeboid phenotype (Fig.4C).
NEDD9 drives Rac1 activity through interaction with GEF VAV2
Previously, it was shown in melanoma cells that NEDD9 activates Rac1 via interaction with the
Rac1-GEF DOCK3 (15). Based on the breast cancer cell expression profiles of different GEFs and
their downstream effectors, several potential Rac1 GEF candidates were examined for their ability to
bind NEDD9 in co-immunoprecipitation experiments including DOCK4, DOCK180, VAV2, Tiam1,
GEF-H1, ARHGEF2, ARHGEF4, DEF6, ECT2, and DBL (Supplementary Table 1). Some GEFs
(such as DEF6, Fig.S6E) were co-immunoprecipitated with NEDD9 using anti-NEDD9 specific
monoclonal (2G9) antibody, however only VAV2 was found to also reciprocally pull down NEDD9
(Fig.4D, Fig.S6F) when immunoprecipitating VAV2. To confirm that VAV2 is required for Rac1
activation in breast cancer cells, active Rac1 pulldowns were performed on cells treated with siCon or
siRNA targeting VAV2 (Fig.4E). VAV2 depletion resulted in a 40-60% reduction in activity of Rac1
(Fig.4F), supporting the notion that VAV2 is a critical downstream effector of NEDD9-dependent Rac1
activation. Importantly, treatment of siCon cells with EHop-016 (42), a small molecular compound
which inhibits Rac1 activation by VAV2 through interaction with Rac1’s VAV2-binding site, resulted in
a reduction in Rac1 activity that was similar to the effect caused by siNEDD9 (Fig.S6G-H). This
inhibition effect by EHop-016 was not found to be additive when combined with NEDD9 depletion.
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Additionally, an increase in Rac1 activity through NEDD9 overexpression was able to be blocked by
VAV2 knockdown, further supporting that NEDD9-induced Rac1 activity is VAV2 dependent (Fig.4G).
Simultaneous targeting of NEDD9 and ROCK/RhoA hinders breast cancer cell motility/invasion
in vitro
Since NEDD9 depletion supports the ROCK/RhoA pathway, knockdown of NEDD9 was
combined with the ROCK-targeting compound Y-27632 to test for an additional therapeutic benefit in
3D invasion assays. NEDD9 depletion alone (via siRNA or sgRNA) led to an increase in amoeboid
morphology and drastically decreased invasion (Fig.5A-E, Vid.S1; Fig.S7A-D, Vid.S2), similar to the
overexpression of constitutively active RhoA (Fig.S7F-J, Vid.S3). Combination of Y-27632+siNEDD9
led to an increase in leading edge speed (extension/retraction), but decreased the cell body speed,
thus rendering the elongated cell immobile (Fig.5C). The directionality and elongation of Y-27632treated cells was significantly increased regardless of NEDD9 depletion (Fig.5D-E). As a
complementary approach, RhoA depletion was performed and resulted in comparable trends (Fig.S8,
Vid.S4). Effects on invasion were also evaluated using Hs578T and HCC1143 cells treated with
siNEDD9, confirming similar results (Fig.S9, Vid.S5-6). Additionally, the AURKA inhibitor MLN8237
was tested as a substitute for siNEDD9 in combination treatments. Cell invasion distance was found
to be decreased with MLN8237/Y-27632 treatment, and was similar to the efficacy of siNEDD9/Y27632 treatment (Fig.S10A-B, Vid.S7). This suggests that MLN8237/Y-27632 could potentially be a
viable combination regimen as well.
NEDD9 is required for collective migration in 3D matrix
To test the impact of NEDD9 depletion on collective tumor cell invasion, cells were seeded in
high density while sandwiched in between two Matrigel layers and time lapse microscopy was
performed. Control cells invaded as strand-like collective streams (“highways”), similar to previous
observations (9) (Fig.5F, Vid.S8). Formation of these streams is diminished following NEDD9
knockdown, which suggests the cells have minimal matrix degradation and/or rearrangement capacity.
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This deficiency in path-generating activity is required for leading cells during collective invasion.
Additionally, cell speed and directionality were both significantly decreased in NEDD9-depleted cells
(Fig.5G-H), which corroborates with a significant reduction in their invasion distance (Fig.5I-K).
Furthermore, inhibition of AURKA yielded a similar decrease in collective cell invasion compared to
NEDD9 depletion (Fig.S10C-D), again suggesting that AURKA could be a viable therapeutic target.
Combination of NEDD9 knockdown and Y-27632 treatment hinders breast cancer cell invasion
and metastasis in vivo
MDA-MB-231-luc2 pTRIPZ-RFP-shControl or shNEDD9 cells were injected into the mammary
fat pad of NSG mice. After 2.5 weeks, mice were treated with the AURKA inhibitor MLN8237 (4 days
on, 3 days off) to prevent pulmonary metastases outgrowth without any effect on the mammary tumor
growth as we previously reported (17). 72 hours post-MLN8237 pretreatment, mice with tumors were
subjected to doxycycline-induced shCon or shNEDD9 expression and administration of Y-27632
compound for 3 weeks (Fig.6A). Primary tumor growth was measured weekly and was significantly
reduced in shNEDD9/Y-27632 combination-treated animals compared to vehicle (Fig.6B-C). At the
end of the study, NEDD9 depletion was confirmed in the mammary tumors by western blot (Fig.6DE). To measure the metastatic ability of the tumor cells, terminal blood samples were collected and
analyzed after euthanization for circulating tumor cells (CTCs) using flow cytometry. Nearly a 40%
reduction in the number of CTCs was documented with shNEDD9 induction, which decreased even
further with addition of Y-27632 (Fig.6F). A significant abatement in the number of metastases per
lung area was seen with NEDD9 knockdown, and an even more pronounced inhibition was seen in
combination with Y-27632 (Fig.6G), supporting our hypothesis that dual targeting of both the
mesenchymal and amoeboid pathways via NEDD9 and ROCK/RhoA can be a promising therapy
against breast cancer metastasis (Fig.6H).
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Discussion
NEDD9 protein is found consistently upregulated in TNBCs and highly correlates with
invasive/metastatic spread (1, 17). Our findings provide a mechanistic explanation for NEDD9-driven
invasion processes and strongly advocates for the combination of anti-NEDD9/AURKA and antiROCK targeting compounds to inhibit these movement signaling cascades. In this study, we report
that deficiency in NEDD9 signaling itself leads to inhibition of key aspects of both mesenchymal and
amoeboid migration in TNBC cells, resulting in substantial hindrance on cell invasion and metastasis.
Similar to results in melanoma (14), NEDD9 deficiency in TNBC cells results in rounded/amoeboid
morphology along with a decrease in the total number of mature (pFAK/pPaxillin positive) adhesions
and an increase in the number of nascent adhesions (40). However, these cells also saw an increase
in long fibrillar adhesions (Fig.S3D). These findings suggest that NEDD9 is also required for the
disassembly of fibrillar adhesions similar to vinculin (43), which regulates the recruitment and release
of focal adhesion proteins in a force-dependent manner (44). The role of NEDD9/HEF1 as a sensor
of altered adhesion states has been previously reported (45). A decrease in disassembly could be due
to matrix metalloprotease inhibition (46), as previously reported by our group (24). Hindered
disassembly of FAs would be in disagreement with a previously noted increase in adhesion turnover
of NEDD9-KO or mutant NEDD9 (Y189A) expressing fibroblasts in 2D cultures (47, 48), however the
structure, composition, and dynamics of adhesions in 2D fibroblasts may be different from 3D tumor
cells.
NEDD9 deficiency led to an increase in myosin-phosphorylated amoeboid-like cells, but this
increase in pMLC2 did not translate to increased collective-cell contractility or invasion in 3D matrix.
This disconnect may suggest a potential de-coupling between the actin filaments and myosin motors
during cell body contraction (49). Alternatively, the inability of NEDD9-deficient cells to disassemble
adhesions as we have suggested would limit amoeboid movement, which is in agreement with our
previous reports on integrin dynamics (32).
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Consistent with past findings, we found that NEDD9 deficiency resulted in over a 50% decrease
in active Rac1, suggesting that NEDD9 is critical for Rac1 activation to occur in TNBC cells. We
discovered that an interaction between NEDD9 and the Rac1-GEF protein VAV2 is required for Rac1
activation. Similar to NEDD9 depletion, loss of VAV2 yields a comparable decrease in Rac1 activity.
Furthermore, the small molecule compound EHop-016, which efficiently blocks the interaction of Rac1
with VAV2 (42), did not cause an additive effect on Rac1 inhibition when given to siNEDD9 cells,
suggesting that NEDD9 and VAV2 share the same pathway to Rac1 activation. The potential clinical
application of this compound has yet to be determined, however another VAV-family targeting drug,
the purine analogue azathioprine, was recently found to inhibit pancreatic cancer metastasis (50).
Additionally, overexpression of NEDD9 increased Rac1 activity, which was abrogated upon depletion
of VAV2, supporting that NEDD9’s influence on Rac1 activation is VAV2-dependent. Selecting NEDD9
as a therapeutic target could potentially be more beneficial than targeting VAV2 due to its upstream
placement in the mesenchymal pathway and the multiple downstream branches that it links to
including VAV2/Rac1 and AURKA/CTTN. The effect of AURKA inhibition on actin dynamics in TNBCs
and its ability to regulate filamentous actin polymerization via phosphorylation of CTTN suggests a
potential mechanistic explanation for the mesenchymal to amoeboid morphology changes observed
upon NEDD9 depletion and provides additional venues to explore CTTN/AURKA signaling in TNBC
metastasis.
In collagen invasion assays, both NEDD9-deficient and MLN8237-treated cells underwent a
drastic reduction in cell invasion. It was anticipated that amoeboid cells could potentially move faster
with a more erratic cell trajectory. While a small decrease in directionality was seen upon NEDD9
depletion, it was not significant. Inhibition of ROCK or RhoA in NEDD9-deficient TNBC cells reverted
them back to an elongated cell shape, but not their original migration proficiency. These combinationtreated cells also had a significant increase in cell directionality - this is likely due to their significant
increase in cell length which was even higher than control cells.
48

The substantially impeded movement of combination-treated cells could be related to the large
difference in speed observed between the CB and LE. LE speed remains high, continuing to protrude
and retract, but the cell is incompetent to degrade matrix and/or make anchor points, due to NEDD9
deficiency. Meanwhile, the cell rear cannot efficiently contract due to inhibition of ROCK/RhoA, leaving
the CB more immobile. This combination therefore results in a severe gap between a stagnant,
immotile CB along with a quickly protruding/retracting, yet functionally impaired LE. These results
support the notion that simultaneous inhibition of both the NEDD9/AURKA and ROCK/RhoA pathways
could be an efficient anti-migratory/metastasis treatment option. These conclusions were further
supported by our findings in an in vivo breast cancer xenograft mouse model, demonstrating a
significant reduction in the number of circulating tumor cells and pulmonary metastases of mice that
received combination treatment. These findings are also in agreement with previously published
reports of NEDD9 depletion showing a decrease in the invasion and dissemination of diverse cancer
types in vivo (1, 2).
In conclusion, while NEDD9-deficient cells may have many hallmarks of amoeboid phenotype,
we have shown that amoeboid movement appears defective in some respects such as decreased cell
contractility. Nonetheless, depletion of RhoA or addition of ROCK inhibitor to NEDD9-deficient cells
provided additional benefit in further hindrance of cell invasion/metastasis. Through concurrent
targeting of these pathways, this approach merits further evaluation as a clinical option to augment
breast cancer patient survival.
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Figure Legends
Fig. 1. TNBC cell morphology changes upon NEDD9 and ROCK inhibition
(A) Western blot analysis of NEDD9 expression in MDA-MB-231, HCC1143, and Hs578T treated with
multiple siRNAs. (B) Brightfield images of MDA-MB-231, HCC1143, and Hs578T cells treated with
siCon or siNEDD9 in 3D collagen I and (C) cell elongation quantified as cell length/width (40
cells/group). (D) Brightfield images of BT549, HCC1395, and SUM159 cells expressing siCon,
siNEDD9, or CA-RhoA, (E) cell elongation quantified as cell length/width (100 cells/group), and (F)
western blots of NEDD9 knockdown and CA-RhoA expression. (G) Brightfield images of TNBC cells,
vehicle or Y-27632 treatment and (H) cell elongation quantified as cell length/width (40 cells/group).
ns, not significant; *p<0.05, student’s t-test vs control.
Fig. 2. NEDD9 depletion increases phosphorylation of MLC2 and decreases phosphorylation
of FAK and paxillin
(A) MDA-MB-231 siCon and siNEDD9 cells in collagen I stained for pMLC2, actin, and Hoechst DNA
dye. Scale bar, 20 µm. (B) Box and whisker plot of pMLC2 relative fluorescence intensity (RFI), n = 3,
20-30 cells/group. Intensity was normalized to the cell area. (C) Western blot and (D) quantification of
MLC2 phosphorylation, n = 3. (E) Collagen gel contraction assay of MDA-MB-231 CRISPR
sgCon/sgNEDD9 cells over 24 hours and (F) quantification of collagen gel area, n = 3. (G) MDA-MB231 siCon and siNEDD9 cells in collagen I stained for pFAKY397 or pPaxillinY31 and Hoechst DNA dye.
Scale bar, 20 µm. (H) Box and whisker plot of pFAKY397 fluorescence and (I) pPaxillinY31 fluorescence,
n = 3, at least 20 cells/group. (J) Quantification of # of focal adhesions per cell, n = 3, at least 20
cells/group. (K) Western blot and quantification of (L) FAK and (M) paxillin phosphorylation. n = 3.
*p<0.05, student’s t-test vs control.
Fig. 3. NEDD9 regulates AURKA-driven phosphorylation of CTTN and stability of actin
filaments
(A) Radioactive in vitro kinase assay of recombinant AURKA and full length WT CTTN proteins using
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radiolabeled P32-ATP, n = 3. WB shows total protein (top and middle) while autoradiograph shows
P32-phosphorylated protein (bottom). (B) Radioactive in vitro kinase assay of recombinant AURKA
and N-term (1-350 aa) and C-term (350-546 aa) CTTN proteins using radiolabeled P32-ATP, n = 3.
WB shows total protein (top and middle) while autoradiograph shows P32-phosphorylated protein
(bottom, 24 hour exposure). (C) Pyrene-actin polymerization assay of AURKA and CTTN, n = 4.
Curves were fit with Boltzmann sigmoidal analysis, *p<0.05. (D) Kymographs of cell membrane of
MDA-MB-231 cells treated with Vehicle or MLN8237 and quantifications of (E) protrusion velocity and
(F) maximum membrane extension. n.d., not detected.
Fig. 4. NEDD9 drives Rac1 activity through interaction with GEF VAV2
(A) Western blot of active-Rac1 pulldown (PD) from MDA-MB-231 siCon/siNEDD9 cells in 3D Matrigel
using GST-PBD conjugated beads. Lane 1: GST-empty beads control. WCL, whole cell lysate. (B)
Quantification of Rac1 activity in 3D collagen and Matrigel (active/total Rac1) by WB. (C) Quantification
of RhoA activity in 3D collagen and Matrigel by G-LISA. (D) Co-immunoprecipitation of HA-VAV2 and
RFP-NEDD9 through IP of each protein. IgG, mouse IgG control. (E) Western blot of active-Rac1
pulldown from MDA-MB-231 siCon/siVAV2 cells and (F) quantification of Rac1 activity. (G) Western
blot of active-Rac1 pulldown from GFP-NEDD9 overexpressing MDA-MB-231 siCon/siVAV2 cells.
Lane 1: GST-empty beads control. WCL, whole cell lysate. Exog, exogenous. Endog, endogenous.
For all experiments: n = 3, *p<0.05, student’s t-test vs control.
Fig. 5. Simultaneous targeting of NEDD9 and ROCK/RhoA hinders breast cancer cell
motility/invasion in vitro
(A) Brightfield outlined cell morphology images (~12 hours), (B) individual cell tracking movement plots
toward FBS chemoattractant (left), box and whisker plots of (C) cell body (CB) and leading edge (LE)
speed, (D) cell body directionality, and (E) cell elongation of MDA-MB-231 cells with siCon/siNEDD9
+ Vehicle/Y-27632 treatment in 3D collagen Ibidi chemotactic invasion movies. Scale bar, 20 µm. n =
3, 30-40 cells per group. ns, not significant; *p<0.05, one-way ANOVA. (F) GFP immunofluorescence
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images and box and whisker plots of (G) cell body speed and (H) cell body directionality of MDA-MB231 pGIPZ-GFP shControl and shNEDD9 cells after 24 hours being densely seeded in a 3D Matrigel
sandwich assay. Scale bar: 20 µm. n = 3, at least 60 cells per group. *p<0.05, student’s t-test vs
control. (I) 3D projection boxes and (J) collective invasion quantification of the amount of MDA-MB231 pGIPZ-GFP shControl/shNEDD9 cells reaching 100 µm invasion distance after 72 hours being
densely seeded in a 3D Matrigel sandwich assay. *p<0.05, student’s t-test vs control. (K) Western
blot of shNEDD9 knockdown in collective invasion assay.
Fig. 6. Simultaneous targeting of NEDD9 and ROCK hinders breast cancer cell invasion and
metastasis in vivo
(A) MDA-MB-231-luc2 TZ RFP-shCon and RFP-shNEDD9 cells injected into the mammary fat pad of
NSG mice were grown for ~3.5 weeks before starting treatment (time 0) for 3 weeks with 10 mg/kg Y27632 and shRNA induction. (B) Weekly images of tumor cells in vivo via bioluminescence signal
which was (C) quantified at the primary tumor site. (D) Western blot and (E) quantification of NEDD9
knockdown in final primary tumors. (F) Quantification of number of RFP-positive circulating tumor cells
in mouse blood by FACS analysis. (G) Quantification of number of visible metastases per area of lung
tissue. (H) Proposed schematic of mesenchymal and amoeboid pathways in breast cancer. n = 5
mice/group. *p<0.05, one-way ANOVA.
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Supplemental Figures

Fig. S1. NEDD9 depletion causes a switch to amoeboid morphology
(A) Brightfield images of outlined siControl and SMARTpool siNEDD9 MDA-MB-231, HCC1143, and
Hs578T cells in 2D and (B) cell elongation quantified as cell length/width (at least 60-70 cells/group).
(C) Scanning electron microscopy images of bovine skin collagen I and Matrigel matrices. (D) Box
and whisker plot of collagen pore cross section area (n = 40 pores). (E) Western blot of NEDD9
knockdown with two CRISPR sgRNAs in MDA-MB-231 cells. (F) Quantification of MDA-MB-231 cell
elongation with SMARTpool CRISPR sgNEDD9 knockdown (at least 120 cells/group). (G) MDA-MB231 siCon and siNEDD9 cells in Matrigel stained for pFAKY397 and DNA dye. (H) Box and whisker plot
of pFAKY397 fluorescence, (I) quantification of # of focal adhesions per cell and (J) box and whisker
plot of pMLC2 fluorescence intensity in Matrigel, n = 3, at least 30 cells/group. Scale bars, 20 μm.
For all experiments: *p<0.05, student’s t-test vs control.
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Fig. S2. NEDD9 depletion decreases phosphorylation of focal adhesion proteins in other BC
cell lines
(A) Western blot and quantification of (B) pFAKY397 and (C) pPaxillinY31 phosphorylation in Hs578T
breast cancer cells. (D) Western blot and quantification of (E) pFAKY397 and (F) pPaxillinY31
phosphorylation in HCC1143 breast cancer cells. n = 3. *p<0.05, student’s t-test vs control.

68

Fig. S3. NEDD9 depletion affects vinculin-containing focal adhesion dynamics
(A) MDA-MB-231 sgCon and sgNEDD9 cells +/- Y-27632 treatment stained for vinculin with
additional stains for phospho-p130casY234, actin, and Hoechst DNA dye. Scale bars, 20 μm. (B)
Quantification of vinculin-positive focal adhesion length. (C) Quantification of # of vinculin-positive
focal adhesions. *p<0.05, one-way ANOVA. (D) Schematic of focal adhesion maturation under
NEDD9 knockdown. NA, nascent adhesion; FA, focal adhesion; fbFA, fibrillar focal adhesion.
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Fig. S4. NEDD9 depletion affects talin-containing focal adhesion dynamics
(A) MDA-MB-231 sgCon and sgNEDD9 cells +/- Y-27632 treatment stained for talin with additional
stains for phospho-p130casY234, actin, and Hoechst DNA dye. Scale bars, 20 μm. (B) Quantification
of talin-positive focal adhesion length. (C) Quantification of # of talin-positive focal adhesions.
*p<0.05, one-way ANOVA.
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Fig. S5. AURKA phosphorylates CTTN in breast cancer cells
Immunoprecipation (IP) of CTTN with mouse monoclonal antibody (4F11) from MDA-MB-231 cells
overexpressing RFP-AURKA and treated overnight with Vehicle or 100 nM AURKA-inhibitor
MLN8237. Western blotted with pan-phospho-serine antibody. IgG, mouse IgG control. WCL, whole
cell lysate. Endog, endogenous.
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Fig. S6. NEDD9 depletion decreases Rac1 activity in other breast cancer cell lines
(A) Western blot of active-Rac1 pulldown from exogenous GST-tagged constitutively active or
dominant negative Rac1-expressing MDA-MB-231 cells to show the activity specificity of GST-PBD
beads. (B) Quantifications of Rac1 activity in 3D collagen and Matrigel (active/total Rac1) in
pulldowns from Hs578T and (C) HCC1143 cells, n = 3, *p<0.05, student’s t-test vs control. (D)
Quantification of Rac1 activity in 3D collagen and Matrigel by G-LISA, *p<0.05, student’s t-test vs
control. (E) Endogenous VAV2 and (F) DEF6 IPs from MDA-MB-231 cells via NEDD9 pulldown, n =
3. IgG, mouse IgG control. (G) Western blot of active-Rac1 pulldown from MDA-MB-231
siCon/siNEDD9 cells + Vehicle/EHop-016 with (H) quantification of Rac1 activity (active/total Rac1).
Lane 1: GST-empty beads control. WCL, whole cell lysate.
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Fig. S7. Depletion of NEDD9 via CRISPR-Cas9 system and overexpression of CA-RhoA
decreases cell invasion and increases round amoeboid phenotype
(A) Brightfield outlined cell morphology images (~12 hours), (B) individual cell tracking movement
plots toward FBS chemoattractant (left), and box and whisker plots of (C) cell body speed and (D)
cell body directionality of MDA-MB-231 sgCon/sgNEDD9 cells in 3D collagen Ibidi chemotactic
invasion movies, 30-40 cells/group. (E) Western blot of exogenous CA-RhoA overexpression in
MDA-MB-231 cells. (F) Brightfield outlined cell morphology images (~12 hours), (G) box and whisker
plot of cell elongation, (H) individual cell tracking movement plots toward FBS chemoattractant (left),
and box and whisker plots of (I) cell body (CB) speed and (J) cell body directionality of MDA-MB-231
control and CA-RhoA overexpressing cells in 3D collagen Ibidi chemotactic invasion movies, 30-40
cells/group. Scale bars, 20 μm. For all experiments: n = 3, *p<0.05, student’s t-test vs control.
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Fig. S8. Simultaneous inhibition of mesenchymal and amoeboid pathways through NEDD9
and RhoA knockdown hinders cell invasion in vitro
(A) Western blot of NEDD9 and RhoA knockdown in MDA-MB-231 cells. (B) Brightfield outlined cell
morphology images (~12 hours), (C) box and whisker plot of cell elongation, (D) individual cell
tracking movement plots toward FBS chemoattractant (left), and box and whisker plots of (E) cell
body (CB) speed and (F) cell body directionality of MDA-MB-231 cells with siCon, siNEDD9, or
siRhoA in 3D collagen Ibidi chemotactic invasion movies, n = 3, 30-40 cells/group. Scale bars, 20
μm. ns, not significant; *p<0.05, one-way ANOVA.
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Fig. S9. Depletion of NEDD9 hinders invasion of other breast cancer cell lines in vitro
(A) Western blot of SMARTpool siNEDD9 treatment in Hs578T and (B) HCC1143 cells. (C-H)
Individual cell tracking movement plots toward FBS chemoattractant (C-D, left) and box and whisker
plots of cell body speed and cell body directionality of (C, E-F) Hs578T and (D, G-H) HCC1143
siCon/siNEDD9 cells in 3D collagen Ibidi chemotactic invasion movies, n = 3, 30-40 cells/group.
*p<0.05, student’s t-test vs control.
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Fig. S10. AURKA inhibition hinders breast cancer cell invasion
(A) Quantification of Euclidean distance and (B) total distance invaded by MDA-MB-231
siCon/siNEDD9 cells (+/- MLN8237 and Y-27632 treatment) in 3D collagen Ibidi chemotactic
individual cell invasion assays, at least 60 cells/group. *p<0.05, one-way ANOVA. (C) 3D projection
boxes and (D) collective invasion quantification of the amount of MDA-MB-231 pGIPZ-GFP
shControl/shNEDD9 cells (+/- MLN8237 and Y-27632 treatment) reaching 100 μm invasion distance
after 72 hours being densely seeded in a 3D matrigel sandwich assay. n = 3, *p<0.05, one-way
ANOVA. ns, not significant.
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Table S1. Co-immunoprecipitation results of NEDD9 with multiple GEF proteins
Results from co-immunoprecipitations of exogenous NEDD9 and multiple different al Rac1 GEFs in
293T cells. Multiple GEFs were found to pull down with NEDD9 protein, but only VAV2 was found to
also reciprocally co-IP NEDD9 when pulling down the GEF protein itself.
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Video Legends
Video S1. Ibidi chemotactic invasion of MDA-MB-231 cells with NEDD9 depletion and ROCK
inhibition
Movie of individual MDA-MB-231 siCon/siNEDD9 cells treated with Vehicle or Y-27632 in 3D collagen
manually tracked over the course of 23 hours. A serum chemoattractant-containing reservoir was
present on the left side of the frame.
Video S2. Ibidi chemotactic invasion of MDA-MB-231 cells with CRISPR sgNEDD9 depletion
Movie of individual MDA-MB-231 sgCon/sgNEDD9 cells in 3D collagen manually tracked over the
course of 23 hours. A serum chemoattractant-containing reservoir was present on the left side of the
frame.
Video S3. Ibidi chemotactic invasion of MDA-MB-231 cells with CA-RhoA overexpression
Movie of individual CA-RhoA expressing MDA-MB-231 cells in 3D collagen manually tracked over the
course of 23 hours. A serum chemoattractant-containing reservoir was present on the left side of the
frame.
Video S4. Ibidi chemotactic invasion of MDA-MB-231 cells with NEDD9 and RhoA depletion
Movie of individual MDA-MB-231 siCon/siNEDD9/siRHOA cells in 3D collagen manually tracked over
the course of 23 hours. A serum chemoattractant-containing reservoir was present on the left side of
the frame.
Video S5. Ibidi chemotactic invasion of Hs578T cells with NEDD9 depletion
Movie of individual Hs578T siCon/siNEDD9 cells in 3D collagen manually tracked over the course of
23 hours. A serum chemoattractant-containing reservoir was present on the left side of the frame.
Video S6. Ibidi chemotactic invasion of HCC1143 cells with NEDD9 depletion
Movie of individual HCC1143 siCon/siNEDD9 cells in 3D collagen manually tracked over the course
of 46 hours. A serum chemoattractant-containing reservoir was present on the left side of the frame.
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Video S7. Ibidi chemotactic invasion of MDA-MB-231 cells with AURKA and ROCK inhibition
Movie of individual MDA-MB-231 cells treated with MLN8237 or Y-27632 in 3D collagen manually
tracked over the course of 23 hours. A serum chemoattractant-containing reservoir was present on
the left side of the frame.
Video S8. Collective invasion of MDA-MB-231 cells with NEDD9 depletion
Movie of collective invasion of densely seeded MDA-MB-231 pGIPZ-GFP shCon/shNEDD9 cells in
3D Matrigel manually tracked over the course of 24 hours.
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Supplemental Materials and Methods
RNAs and plasmids
pGIPZ and pTRIPZ-shControl/NEDD9 shRNAs (ThermoFisher Scientific), Control siRNA
(Bioneer and Origene), NEDD9 siRNA (2-siRNA SMARTpool of 1: Dharmacon #D-019466-22 and 2:
#D-019466-23), RhoA siRNA (3-siRNA SMARTpool: Origene #SR300278A, SR300278B, and
SR300278C), and VAV2 siRNA (3-siRNA SMARTpool: Origene #SR305062A, SR305062B, and
SR305062C) were used based on manufacturers’ recommendations. lentiCRISPRv2 plasmid was a
gift from Feng Zhang (Addgene plasmid #52961) (1). NEDD9 sgRNA (sequence #1:
GTACCCATCCAGATACCAAA, #2: TGTGGAGGATGAGTTCCGGG) was designed using Broad
Institute sgRNA Designer online tool and subcloned into lentiCRISPRv2 as described (2). pEGFP-C3Rac1-T17N dominant negative (DN), pEYFP-C1-Rac1-Q61L constitutively active (CA), and pEGFPC3-RhoA-Q63L (CA) plasmids were a gift from Dr. Michael Schaller (West Virginia University). pGSTparallel2-CTTN-WT, pGST-parallel2-CTTN-Nterm-1-350, and pGST-parallel2-CTTN-Cterm-350-546
were a gift from Dr. Scott Weed (West Virginia University). pDEST/LifeAct-mCherry-N1 was a gift from
Robin Shaw (Addgene plasmid #40908) (3). pGEX-6P-1 (Amersham) and pGEXTK-Pak1 70-117 (gift
from Jonathan Chernoff, Addgene plasmid #12217) plasmids were used to produce GST-control and
GST-Pak1 binding domain (PBD) proteins respectively for pulldowns. pcDNA3-FLAG-NEDD9 and
pcDNA3.1-mRFP-NEDD9 were previously reported (4). pC.HA Vav2 was a gift from Joan Brugge
(Addgene plasmid # 14554) (5). YF-Tiam1 was a gift from Tobias Meyer (Addgene plasmid # 20154)
(6). ARHGEF2 (GE Healthcare), DEF6 (PlasmID), ARHGEF4 (PlasmID), and Dbl (gift from Dr. Xosé
Bustelo, University of Salamanca-CSIC) were subcloned into pcDNA3.1-6HA vector. pCEV32F3ECT2 plasmid was a gift from Dr. Toru Miki (Nagaoka University of Technology). pCMV5-HA3-GEFH1 plasmid was a gift from Dr. Celine de Mardirossian (The Scripps Research Institute). The indicated
above plasmids or RNAs were introduced via nucleofection (Amaxa) according to manufacturer’s
recommendation or virus infection (293T packaging cells, LifeTechnologies) as previously described
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(7).
Matrix pore size analysis
Confocal reflection microscopy: The lattice of 1.5mg/ml 3D bovine skin collagen I (Advanced
BioMatrix) was imaged using confocal reflection microscopy (Zeiss-LSM510, 63X objective with 2µm
steps) as previously described (8). The images were rendered as a 3D projection using ImageJ
software (NIH) (9) and pore size was quantified by manually outlining visible holes in the lattice to
calculate cross sections.
Scanning electron microscopy: 1.5mg/ml collagen and 4mg/ml Matrigel (Corning) were fixed
with glutaraldehyde and dehydrated with increasing ethanol. Matrices were then dried and sputtered
for 120 seconds with a Denton Desk V Sputter. Samples were imaged using a Hitachi S-4700F
scanning electron microscope.
Western blotting
Samples were prepared in Laemmli buffer, resolved in Bolt 4-12% Bis-Tris/Novex acrylamide
gel (LifeTechnologies), transferred onto 0.45µm PVDF membrane (Millipore), and blocked with 5%
milk or bovine serum albumin in PBS or TBS with 0.05% Tween-20 (Fisher). Antibodies used included:
NEDD9 (2G9, (10)), α-tubulin (Sigma), pMLC2Thr18/Ser19 (Cell Signaling), MLC2 (Cell Signaling),
pPaxillinY31 (Biosource), paxillin (Calbiochem), pFAKY397 (Calbiochem), FAK (Calbiochem), AURKA
(AurA-N, custom (4)), CTTN (4F11, gift from Dr. Scott Weed, West Virginia University), CTTN (H-191,
Santa Cruz), pan-phospho-serine (Zymed), Rac1 (Cytoskeleton), RhoA (Cell Signaling), GAPDH
(Millipore), VAV2 (Santa Cruz), DEF6 (Santa Cruz), HA-tag (Cell Signaling), Flag-tag (Cell Signaling),
and HRP-conjugated anti-rabbit/anti-mouse (Jackson ImmunoResearch). Protein bands were
detected with HyGLO chemiluminescent HRP detection reagent (Denville), imaged (Syngene G:Box),
and quantified using GeneTools 4.01 software from Syngene as previously described (7).
Immunofluorescence
In addition to antibodies already described for WB, additional antibodies/stains used for IF
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included Rhodamine-Phalloidin (Cytoskeleton), Vinculin (Santa Cruz), Talin (Santa Cruz), Tensin (gift
from Dr. Michael Schaller, West Virginia University), p-p130casY234 (Open Biosystems), Alexa Fluor
647-phalloidin (Invitrogen), anti-rabbit or anti-mouse Alexa Fluor 488/555/647-IgG (Jackson
ImmunoResearch), and Hoechst-33342 DNA dye (LifeTechnologies). Coverslips were mounted using
ProLong anti-fade reagent (LifeTechnologies) and imaged using a Zeiss-LSM510 microscope and
63X objective and rendered as 3D projections using ImageJ software. Relative fluorescence intensity
(RFI) was measured as the mean gray value per cell area in ImageJ. Focal adhesion length was
measured and the number of adhesions was counted per cell and normalized to the total cell area.
Immunoprecipitation and western blot of cortactin phosphorylation in cells
AURKA overexpression was induced with doxycycline overnight in MDA-MB-231 pLUTZmRFP-AURKA cells and then treated for 24 hours with 100nM MLN8237. Cells were lysed with PTY
lysis buffer and processed as previously described (10). Lysates were precleared with protein-A/Gsepharose (GE Healthcare) for 1 hour at 4°C. Mouse IgG control or anti-CTTN (4F11) antibodies were
added to precleared lysates overnight rotating at 4°C. Protein-A/G-sepharose beads preblocked with
bovine serum albumin were added to the rotating tubes for 2 hours. Beads were allowed to settle for
15 minutes on ice, then washed three times with PTY buffer. Beads were resuspended in Laemmli
buffer and boiled at 100°C to elute proteins for gel electrophoresis and western blotting. Pan-phosphoserine antibody (Zymed) was used to stain for cortactin phosphorylation on the WB and total cortactin
was stained with another cortactin specific antibody (H-191, Santa Cruz).
Quantification of cell invasion movies
Cell elongation was measured as a function of cell length to cell width at the midpoint of the
movies to give cells adequate time to adapt to their surroundings and capture their morphology during
invasion. Cell body and leading edge speeds were calculated by manually tracking physical movement
of either the main cell body or the protruding/retracting leading edge using MTrackJ plugin for ImageJ
(11). Cell body directionality was measured from the tracking data as a function of Euclidean distance
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from the initial starting point over the total distance traveled. Individual cell movement tracking plots
were made using help from Ibidi Chemotaxis and Migration Tool software.

83

Supplemental References

1.

Sanjana NE, Shalem O, Zhang F. Improved vectors and genome-wide libraries for CRISPR

screening. Nat Methods. 2014;11(8):783-4. doi: 10.1038/nmeth.3047. PubMed PMID: 25075903;
PMCID: PMC4486245.
2.

Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelsen TS, Heckl D, Ebert BL, Root

DE, Doench JG, Zhang F. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science.
2014;343(6166):84-7.

doi:

10.1126/science.1247005.

PubMed

PMID:

24336571;

PMCID:

PMC4089965.
3.

Smyth JW, Vogan JM, Buch PJ, Zhang SS, Fong TS, Hong TT, Shaw RM. Actin cytoskeleton

rest stops regulate anterograde traffic of connexin 43 vesicles to the plasma membrane. Circ Res.
2012;110(7):978-89. doi: 10.1161/CIRCRESAHA.111.257964. PubMed PMID: 22328533; PMCID:
PMC3621031.
4.

Kozyreva VK, McLaughlin SL, Livengood RH, Calkins RA, Kelley LC, Rajulapati A, Ice RJ,

Smolkin MB, Weed SA, Pugacheva EN. NEDD9 regulates actin dynamics through cortactin
deacetylation in an AURKA/HDAC6-dependent manner. Mol Cancer Res. 2014;12(5):681-93. doi:
10.1158/1541-7786.MCR-13-0654. PubMed PMID: 24574519; PMCID: 4020952.
5.

Moores SL, Selfors LM, Fredericks J, Breit T, Fujikawa K, Alt FW, Brugge JS, Swat W. Vav

family proteins couple to diverse cell surface receptors. Mol Cell Biol. 2000;20(17):6364-73. PubMed
PMID: 10938113; PMCID: PMC86111.
6.

Inoue T, Heo WD, Grimley JS, Wandless TJ, Meyer T. An inducible translocation strategy to

rapidly activate and inhibit small GTPase signaling pathways. Nat Methods. 2005;2(6):415-8. doi:
10.1038/nmeth763. PubMed PMID: 15908919; PMCID: PMC3579513.
7.

Loskutov YV, Kozyulina PY, Kozyreva VK, Ice RJ, Jones BC, Roston TJ, Smolkin MB, Ivanov

AV, Wysolmerski RB, Pugacheva EN. NEDD9/Arf6-dependent endocytic trafficking of matrix
84

metalloproteinase 14: a novel mechanism for blocking mesenchymal cell invasion and metastasis of
breast cancer. Oncogene. 2014. doi: 10.1038/onc.2014.297. PubMed PMID: 25241893.
8.

Wolf K, Te Lindert M, Krause M, Alexander S, Te Riet J, Willis AL, Hoffman RM, Figdor CG,

Weiss SJ, Friedl P. Physical limits of cell migration: control by ECM space and nuclear deformation
and

tuning

by

proteolysis

and

traction

force.

J

Cell

Biol.

2013;201(7):1069-84.

doi:

10.1083/jcb.201210152. PubMed PMID: 23798731; PMCID: 3691458.
9.

Artym VV, Matsumoto K. Imaging cells in three-dimensional collagen matrix. Curr Protoc Cell

Biol. 2010;Chapter 10:Unit 10 8 1-20. doi: 10.1002/0471143030.cb1018s48. PubMed PMID:
20853341; PMCID: PMC2988473.
10.

Pugacheva EN, Golemis EA. The focal adhesion scaffolding protein HEF1 regulates activation

of the Aurora-A and Nek2 kinases at the centrosome. Nat Cell Biol. 2005;7(10):937-46. PubMed PMID:
16184168.
11.

Meijering E, Dzyubachyk O, Smal I. Methods for cell and particle tracking. Methods Enzymol.

2012;504:183-200. doi: 10.1016/B978-0-12-391857-4.00009-4. PubMed PMID: 22264535.

85

CHAPTER 3: SUMMARY

The work detailed in this dissertation uncovers significant insights into the mechanisms
and therapeutic viability of inhibiting NEDD9-driven mesenchymal migration and invasion in
combination with amoeboid pathway targeting. Triple negative breast cancer has remained an
extremely prevalent and deadly cancer with minimal treatment options available for patients,
especially for those patients who are metastatic. Metastasis from the primary tumor site is the
most life threatening aspect of TNBC, making the inhibition of cancer cell movement an ideal
treatment strategy in order to stop its spread to distant organs.
In this project, we report a novel relationship between NEDD9 and the Rac1 GEF VAV2
in breast cancer, where NEDD9 expression contributes to Rac1 activation in a VAV2-dependent
manner. This VAV2-Rac1 signaling cascade in combination with another NEDD9-driven
signaling network through AURKA-HDAC6-CTTN, both of which contribute to actin
polymerization dynamics and subsequent lamellipodia/invadopodia formation, makes NEDD9
a prime therapeutic target to downregulate mesenchymal movement. In addition, we report the
novel finding that NEDD9 inhibition by itself seems to hinder aspects of both mesenchymal and
amoeboid migration phenotypes. These cells lose many mesenchymal characteristics and gain
an amoeboid-like phenotype – becoming more rounded, losing large mature focal adhesions
and gaining nascent adhesions, and increasing phosphorylation of myosin light chain.
Nevertheless, while appearing amoeboid, they are functionally reduced by not translating these
amoeboid features into increased cell contractility in collagen gel assays. This may be linked to
some disruption between the myosin motors and actin filaments or a deficiency in adhesion
disassembly – future work on this topic will be interesting to pursue.
Furthermore, we report that inhibition of NEDD9 causes a severe decrease in breast
cancer cell invasion, pulmonary metastases, and circulating tumor cells in the mouse blood
stream, which can be exacerbated even further through simultaneous treatment with ROCK86

targeting compounds. Similar results in invasion inhibition were obtained through targeting of
AURKA and RhoA proteins. Combination of such treatments, which impede critical components
of both mesenchymal and amoeboid pathways, yields cells with very long morphology that have
thin needle-like leading edge protrusions and lagging cell rears, possibly due to reduced MMP
activation in the front and a deficiency in rear cell contractility to bring the cell forward. These
results highlight the potential for NEDD9 as a promising new therapeutic target, and
additionally, highlights the dual pathway inhibition strategy as a viable and encouraging
approach which merits further study for its possible application into clinical trials for human
breast cancer patients.
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